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Background: Atherosclerosis is the primary cause of coronary heart disease (CHD), preceding the onset of
cardiovascular disease by decades in most cases. Here we examine the association between single nucleotide
polymorphisms (SNPs) integrated on Metabochip and coronary artery calcification (CAC), a valid risk factor for CHD,
in an unselected, population-based German cohort.
Methods: The Metabochip is a custom iSELECT array containing >195,000 SNPs that was designed to support
large-scale follow-up of putative associations for metabolic and cardiovascular-associated traits. We used
generalized linear regression models to explore the impact of Metabochip SNPs on quantitative CAC in 4,329
participants.
Results: The 9p21 variant, rs1537373, was most strongly associated (Beta = 0.30; 95% confidence interval (CI) = 0.21-0.39;
p = 4.05x10-11) with quantitative CAC. The second strongest association with CAC was with rs9349379 in the phosphatase
and actin regulator 1 gene, PHACTR1, (Beta = 0.30; 95% CI = 0.22-0.40; p = 4.67x10-11). Both SNPs remained nominally
significant in dichotomized analyses for the presence of any CAC (odds ratiors1537373 (OR) = 1.19; 95% CI = 1.07-1.31;
p = 0.001 and ORrs9349379 = 1.26; 95% CI = 1.14-1.40); p = 1.5x10
-5). Fine mapping of the 9p21 and PHACTR1 gene region
revealed several other SNPs that were strongly associated with CAC.
Conclusion: We demonstrate that SNPs near 9p21 and in PHACTR1 that have previously been shown to be associated
with CHD are strongly associated with CAC in the Heinz Nixdorf Recall Study cohort. Our findings suggest that the 9p21
and 6q24 loci might be involved in cardiac outcome via promoting development of atherosclerosis in the coronary
arteries.
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Atherosclerosis is the primary cause of coronary heart
disease (CHD), one of the key causes for death and mor-
bidity in the industrialized world [1,2]. Atherosclerosis in
the arterial wall precedes the onset of most cases of clinic-
ally apparent cardiovascular disease by decades [3]. Cor-
onary artery calcification (CAC) is one of the most
sensitive and specific markers of coronary atherosclerotic* Correspondence: sonali.pechlivanis@uk-essen.de
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distribution, and reproduction in any mediumplaque burden. CAC quantification has been shown to im-
prove the ability to predict future CHD events [4,5]. Nu-
merous environmental and genetic factors have been
demonstrated to influence CAC, and strong heritability of
CAC has been shown to account for around 40% of the
observed genetic variance [6-8]. Several CHD risk factors,
including male gender, age, elevated blood pressure, low-
density lipoprotein and diabetes, have been shown to be
related with CAC [9-12].
Several genome-wide association studies (GWASs)
identified novel gene loci for CHD, to which CAC is one
of the precursors [13-25]. The CHARGE consortiumtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Characteristics of the study population*
Variable Males (n = 2158) Females (n = 2171)
Age, years† 59.8 ± 7.80 59. 7 ± 7.80
Known coronary heart disease* 223 (10.3) 62 (2.9)
CAC score ‡ 76. 5 (6.7; 351.8) 2.1 (0.0; 43.8)
Loge(CAC score + 1)
‡ 4.35 (2.0; 5.9) 1.13 (0.0; 3.8)
Presence of any CAC*
0 337 (15.6) 948 (43.7)
> 0 1821 (84.2) 1223 (56.3)
† Data are given as mean ± SD.
* Data are given as number (percentage).
‡ Data are given as median (quartile 1; quartile 3).
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several single nucleotide polymorphisms (SNPs) located
on chromosome 9p21 and the phosphatase and actin
regulator 1 gene, PHACTR1 [26].
While genome-wide findings have often been replicated
for individual SNPs (at α = 5 × 10-8), causal variants could
not be identified using classical fine mapping of a limited
number of markers in most cases due to inadequate sample
availability or the lack of defined phenotypes information.
The next generation of high-density custom SNP array, the
Metabochip, was designed to support fine-mapping. About
200,000 SNPs related to atherosclerotic-cardiovascular and
metabolic traits are embedded on the Metabochip [27].
Thus, the Metabochip is a state-of-the-art summary of rele-
vant genetic variability which will be explored in this study.
Only few studies to date have assessed the role of gen-
etic factors for subphenotypes, such as CAC, of coronary
artery disease (CAD). The examination of specific genetic
variations affecting CAC may help explain the essential
mechanisms leading to CHD and might aid development
of strategies to predict and prevent CHD. Here we aimed
to further this effort by evaluating SNPs associated with
CAC using the Metabochip in unselected, population-
based participants in the German Heinz Nixdorf Recall
Study. Since the Metabochip also includes the loci
detected by the CHARGE consortium [26], our study can
also be regarded as an independent replication in a second
cohort.Methods
Study population
We used baseline data from the Heinz Nixdorf Recall
Study (Risk Factors, Evaluation of Coronary Calcium
and Lifestyle), comprising 4,814 participants spanning
45–75 years of age. Participants were randomly selected
from registration lists between 2000 and 2003 from the
densely populated Ruhr metropolitan area in Germany
(residents of Essen, Bochum and Mühlheim). We followed
a study which previously described study rationale and de-
sign [28]. Information for genotype, gender, age and CAC
was available for 4,329 of 4,814 participants (Table 1).
Baseline CHD was assessed as self-report of previous
events (myocardial infarction and/or revascularization
of coronary arteries including balloon dilation and coron-
ary bypass surgery). CAC was assessed by non-enhanced
electron-beam CT (C-150 scanner, GE Imatron, San
Francisco, CA, USA), as previously described [28]. The
study was approved by the local ethics committees, and
conducted in accordance with the Declaration of Helsinki
and guidelines for good epidemiological practice, in-
cluding extended quality management procedures and
recertification according to DIN ISO 9001:2001. Informed
consent was obtained from all participants.SNP genotyping
Lymphocyte DNA was isolated from EDTA anti-
coagulated venous blood using the Chemagic Magnetic
Separation Module I (Chemagen, Baesweiler, Germany).
Genotyping was performed on Metabochip BeadArrays
(Illumina, San Diego, CA, USA). Quality control utilized
the PLINK (v1.07) software package [29]. Genotyping
was conducted on a total of 4,570 samples, of which 52
samples were excluded from data analysis because of i)
gender inconsistency, ii) identical-by-state was estimated
to measure the degree of recent shared ancestry for a
pair of individuals. We removed one individual from
each pair of putatively-related samples defined as an
identity by descent value greater than 0.185 or iii) a sam-
ple call rate less than 97%. Out of the 196,725 SNP
probes arrayed on Metabochip, 4,464 were excluded be-
cause they had call rates less than 95% or because the
Hardy Weinberg equilibrium Pexact was less than 1×10
-4.
Statistical analyses
The association between each SNP and the loge trans-
formed CAC score +1 was analysed using linear regres-
sion with adjustment for age and gender in an additive
genetic model as described previously [30]. Logistic re-
gression was used for the sensitivity analysis of binary
CAC outcome (CAC > 0 as presence and CAC = 0 as ab-
sence of CAC adjusted for gender and age). All analyses
were repeated after excluding individuals who had CHD
at baseline (n = 285), resulting in a study sample size of
4,035. Gender-stratified analyses were also performed for
the top SNPs. A large proportion of Metabochip consists
of SNPs for the fine mapping of loci that were robustly
associated in meta-analysis [27]. To address the between-
marker linkage disequilibrium (LD), we first used the
pruning technique implemented as “clump” procedure in
PLINK [29]. This procedure selects all SNPs having nom-
inal p-values ≤ 0.0001 that have not already been clumped
(denoted as index SNPs). Each index SNP then forms
clumps with other SNPs that are within ± 250 kb from
the index SNP and that are in LD with the index SNP
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associated with CAC, a conditional analysis was performed
in PLINK using linear regression adjusted for the covariates
age and gender, and the lead SNP at the neighboring
signals. We applied a conservative Bonferroni correction
with a significance level of α = 2.6×10-7 (0.05/192261). A p-
value between 2.6×10-7 and 1×10-5 was considered as mod-
erate evidence for association. SNPs having p ≤ 1.0×10-5
within the "clump" of significant SNPs are reported in
Additional file 1: Table S1. All other SNPs with p ≤ 1.0×10-5
are reported in Additional file 2: Table S2. SNPs reported
to be associated with CAC by the CHARGE consortium
and SNPs reported to be associated with CHD by the
CARDIOGRAM consortium are listed in Additional file 3:
Table S3 [23,26]. Power calculations were made using the
QUANTO Version 1.2.3 software (http://hydra.usc.edu/
gxe) considering a minor allele frequency ≥ 20% and
α = 2.6×10-7 (two-sided). Power was over 90% for the
3,044 individuals with CAC > 0 assuming a standard
normally distributed quantitative trait locus and a
standardized effect size of 0.2 in units of standard
deviations for each risk allele under an additive mode of
inheritance without dominance effects. Thus, our study
was well powered to detect a relatively strong effect size of
quantitative CAC predisposing variants when controlling
for multiple testing. For the gender-stratified analyses with
CAC > 0, power was over 38% for males (n = 1,821) and
over 12% for females (n = 1,223). We reported 95% confi-
dence intervals (95% CI) for all estimates and nominal,
two-sided p-values that are, unless otherwise stated, not
adjusted for multiple testing. All analyses were done using
PLINK v1.07 [29].
Results
SNPs associated with coronary artery calcification
The lead SNPs having p ≤ 2.6×10-7 in each clump was iden-
tified by calculating the effect size estimators (Betas) for the
linear regression models with quantitative transformed
CAC (loge(CAC score + 1)) (Table 2). The strongest associ-
ation was observed for rs1537373 on chromosome 9p21
(Beta = 0.30; 95% CI = 0.21-0.39; p = 4.05×10-11). Even in
the dichotomized CAC analysis, rs1537373 remained nom-
inally significant (p = 0.001) with an increased risk for theTable 2 Results of the genetic association analyses for loge(C
model), gender and age as predictors in a linear regression m







9 CDKN2A/2B rs1537373 22093341 G (0.47) 0.30 (0.21-0.39)
rs10965219 22043687 G (0.48) 0.25 (0.16-0.39)
6 PHACTR1 rs9349379 13011943 G (0.39) 0.30 (0.22-0.40)
CHR Chromosome number; SNP single nucleotide polymorphism; MAF minor allele
calcium and CHD coronary heart disease.presence of CAC (odds ratio for each G risk allele = 1.19;
95% CI = 1.07-1.31). The rs10965219 SNP was also
associated with quantitative CAC (Beta = 0.25; 95%
CI = 0.16-0.39; p = 1.32×10-7). It belongs to a separate
clump and is located 50kb upstream of rs1537373. In the
clump including rs1537373, 45 additional SNPs are
located that were also associated with CAC (p ≤ 1×10-5,
Additional file 1: Table S1). Similarly, 66 SNPs were also
associated (p ≤ 1.0×10-5) with CAC within the clump in-
cluding the rs10965219 SNP. Apart from SNPs at the
chromosome 9p21 locus, the rs9349379 SNP located in
the phosphatase and actin regulator 1 gene (PHACTR1)
on chromosome 6p24 was significantly associated with
CAC (Beta = 0.30; 95% CI = 0.22-0.40; p = 4.67×10-11). No
other SNP besides rs9349379 was present in this clump
that was significantly associated with quantitative CAC
(p ≤ 1.0×10-05). SNP rs9349379 was also nominally sig-
nificant in the dichotomized analysis with an increased
risk for presence of CAC (odds ratio for each G risk
allele = 1.26; 95% CI = 1.14-1.4; p = 1.47×10-5). In a
sensitivity analysis, we excluded all participants with
prevalent CHD at baseline. The beta estimates for this
analysis hardly changed (Table 2), with the largest change
(Beta = 0.04, from 0.30-0.26) observed for rs1537373 at
chromosome 9p21. In an explorative gender-stratified
analysis (Table 3), the chromosome 9p21 SNPs showed a
descriptively stronger effect for association with CAC in
males compared to females. On the other hand, the effect
of association for rs9349379 in the PHACTR1 gene with
CAC was stronger in females as compared to males.
However, only rs10965219 showed a marginally signifi-
cant genotype and gender interaction (after Bonferroni
correction) (Betars10965219xgender = −0.23; 95% CI = −0.4
to −0.05); p = 0.01).
Since several separate signals at the 9p21 locus were
associated with CAC in our study, we carried out conditional
analyses to better understand these associations. The effect
of rs1537373 remained (Beta = 0.24; 95% CI = 0.13-0.35;
p = 1.64×10-5), even after adjusting for the neighbouring
lead SNP rs10965219. However, effect of rs10965219
almost disappeared (Beta = 0.06; 95% CI = −0.002 to 0.22);
p = 0.06) after adjusting for rs1537373. Of the 2 associated
9p21 region SNPs only rs1537373 remained significantlyAC score + 1) using Metabochip SNPs (additive genetic
odel
1) loge(CAC +1) without CHD dichotomized CAC
P Beta (95% CI) P OR (95% CI) P
4.05x10-11 0.26 (0.17-0.35) 1.52x10-8 1.19 (1.07-1.31) 0.001
1.32x10-7 0.23 (0.14-0.32) 1.28x10-6 1.16 (1.05-1.29) 0.005
4.67x10-11 0.31 (0.22-0.40) 3.48x10-11 1.26 (1.14-1.4) 1.47x10-5
frequency from our data; 95% CI 95% confidence interval; CAC coronary artery
Table 3 Results of the genetic association analyses for loge(CAC score + 1) using Metabochip SNPs (additive genetic
model) and age as predictors in a linear regression model for females and males
CHR Gene SNP Physical
position
Gender-SNP Interaction Females Males
Beta (95% CI) P Beta (95% CI) P Beta (95% CI) P
9 CDKN2A/2B rs1537373 22093341 −0.07 (−0.25 to 0.11) 0.44 0.27 (0.15-0.39) 1.28x10-5 0.34 (0.21-0.47) 6.76x10-7
rs10965219 22043687 −0.23 (−0.41 to -0.06) 0.01 0.13 (0.01-0.26) 0.03 0.36 (0.23-0.50) 1.25x10-7
6 PHACTR1 rs9349379 13011943 0.08 (−0.01 to 0.27) 0.37 0.35 (0.23-0.48) 3.5x10-8 0.27 (0.14-0.41) 7.58x10-5
CHR Chromosome number; SNP single nucleotide polymorphism; MAF minor allele frequency from our data; 95% CI 95% confidence interval; CAC coronary
artery calcium.
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suggesting that rs1537373 is the only independent 9p21
region signal to be associated with CAC in our study.
In silico analyses of previously reported loci for CAC
(CHARGE) and CAD (CARDIOGRAM) for the association
with CAC using Metabochip
We also looked to verify associations of SNPs reported by
the CHARGE consortium with CAC in our independent
cohort [26]. Out of the 8 SNPs reported by CHARGE, 4
were present on the Metabochip. We confirmed the as-
sociation of rs1333049 (near CDKN2A/B), rs9349379
(PHACTR1) and rs2026458 (PHACTR1) with CAC in our
study with same direction of effect (all p < 2.84×10-5;
Additional file 1: Tables S1 and Additional file 2: Table S2).
We observed no evidence for an association of SNPs in the
COL4A1/COL4A2 gene (rs3809346 and rs4773144) with
CAC in our study cohort (minimal uncorrected p = 0.19).
We also looked for association of other SNPs located in this
region that were present on the Metabochip with CAC.
This included a total of 1,379 SNPs, of which 35 had
p-values between 0.005–0.05 (data not shown). Other
CHARGE discovery SNPs rs6604023 (near CDC7),
rs6783981 (SERPINI1), rs17676451 (HAL) and rs8001186
(near IRS2) were not present on Metabochip. As a proxy
for these, we also looked for SNPs present in the
SERPINI1 and HAL gene regions and located ± 100 kb
from rs6604023 and rs8001186, respectively. No SNP
located within ±100 kb of rs6604023, rs8001186 or
rs6783981 was associated with CAC (all p > 0.09), and
only the rs1085997 SNP, located 9.5 kb downstream of
rs17676451 (r2 = 0.01, D' = 0.57), was found to be nomin-
ally associated with CAC (Beta = 0.19; 95% CI = 0.05-0.32;
p = 0.006).
Similarly, we assessed the association of the CAD SNPs
reported by the CARDIOGRAM consortium with the
occurrence of CAC in our study [23]. Nineteen of 25 SNPs
reported by the CARDIOGRAM consortium were present
on the Metabochip. Nine SNPs were nominally associated
with CAC in our study (all p < 0.04). Seven SNPs [rs599839
(SORT1), rs17465637 (MIA3), rs12526453 (PHACTR1),
rs1746048 (CXCL12), rs9982601 (MRPS6), rs17114036
(PPAP2B) and rs3825807 (ADAMTS7)] showed same direc-
tion of effect for CAC and rs2306374 (MRAS) andrs579459 (ABO) SNPs showed opposite direction of effect
for CAC as reported by CHARGE CAC GWAS (Additional
file 3: Table 3).
Discussion
Here we identified several SNPs at two loci on chromo-
some 9p21 and on chromosome 6p24 (PHACTR1) that
are strongly associated with CAC in a population-based
cohort. In addition, we confirm associations of rs1333049
(near CDKN2A/2B) and rs9349379 (PHACTR1) with
CAC that were previously reported by the CHARGE con-
sortium in an independent cohort.
Recent GWASs have identified a number of SNPs at
9p21 that are strongly associated with CAC and CHD
[18,19,21,22,26,31]. A study to identify potential tran-
scriptional regulatory elements at the 9p21 CAD locus
showed that rs10757278, which has been consistently
associated with CHD, lies in the 9th enhancer region,
where most of the CAD associated variants are located,
and disrupts a transcription binding site for the signal
transducer and activator of transcription 1 (STAT1) [32].
STAT1 mediates response to inflammation, which is
associated with angiogenesis and atherosclerotic patho-
genesis in endothelial tissue [32-34]. The rs10757278
SNP is in strong LD with the variant detected here,
rs1537373 (r2 = 0.93, D' = 0.97), and is also strongly
associated with quantitative CAC by itself (Additional
file 1: Table S1). Recent studies showed that the CAD
risk interval regulates cardiac CDKN2A/B expression,
and affects CAD progression by altering vascular cell
proliferation [35,36]. Thus, using the Metabochip fine-
mapping approach, we demonstrate that several com-
mon variants lying in the important region on chromo-
some 9p21 are associated with CAC. Our independent
finding is a robust replication of the CAC GWAS
finding of the CHARGE consortium. Taken together, the
chromosome 9p21 region is the most interesting candi-
date for advanced functional studies or animal models
focussing on atherosclerosis.
The second strongest signal was found for rs9349379
in the PHACTR1 gene. This SNP lies in the intronic re-
gion of PHACTR1 gene. The LD values between
rs9349379 and two previously associated CHD SNPs,
rs12526453 and rs1332844, are r2 = 0.32, D' = 0.96 and
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inhibitor of protein phosphatase 1 (PP1), an enzyme that
dephosphorylates serine and threonine residues in a
range of proteins [37]. PHACTR1 contains 8 predicted
sites for protein kinase A phosphorylation and 7 predicted
sites for protein kinase C phosphorylation, and phosphor-
ylation at these sites is suggested to regulate PP1-substrate
interactions [37]. Although both loci were strongly
associated with CAC in our study, we were unable to elu-
cidate the cause behind these associations. Additional
functional studies, combined with SNP data, are needed
to discover the cause behind SNP associations.
Our top findings varied somewhat for gender. Of course,
such findings require a replication in larger samples. On
the other hand, gender-specific effects might be more fre-
quently detectable for CAC given the very different CAC
distributions in men and women [38]. Finally, the absence
of previously reported association of SNPs from CHARGE
and CARDIOGRAM may be either due to the smaller
numbers of participants investigated here, or may result
from confounding factors that were not controlled for.
Conclusion
We demonstrate that genetic variants near 9p21 and
PHACTR1 that have been previously shown to be
associated with CHD are strongly associated with CAC
in our study. These finding suggests that both loci might
be involved in the cardiac outcome by promoting devel-
opment of atherosclerosis in the coronary arteries.
Additional files
Additional file 1: Table S1. Result of the SNPs belonging to the same
clump of the top associated SNP. The SNPs in the clump of the top
associated SNP are selected based on pruning technique implemented
as clump procedure in PLINK. SNPs marked in bold are the top
associated SNP which are presented in Table 2.
Additional file 2: Table S2. Result of the SNPs belonging to the same
clump of SNPs associated with P ≤ 1x10-05 for loge(CAC score + 1). SNPs
marked in bold are the top associated SNP of each clump.
Additional file 3: Table S3. Result of association for loge(CAC score + 1)
with SNPs associated with coronary artery disease in CARDIOGRAM and
coronary artery calcification in CHARGE.
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